Published in Br J Pharmacol on August 01, 1970
A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol (1970) 2.78
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm (2008) 1.96
Investigations to characterize a new anti-arrhythmic drug, ORG 6001 including a simple test for calcium antagonism. Br J Pharmacol (1976) 1.71
Use of amiodarone in bradycardia-tachycardia syndrome. Br Heart J (1978) 1.67
Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias. Br Heart J (1980) 1.64
Effects of amiodarone on thyroid function in patients with ischaemic heart disease. Br Heart J (1975) 1.63
Class 3 antiarrhythmic action in man. Observations from monophasic action potential recordings and amiodarone treatment. Br Heart J (1973) 1.60
The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone. Br Heart J (1984) 1.49
Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors. Br J Pharmacol (1970) 1.47
Arrhythmia in hypertrophic cardiomyopathy. II: Comparison of amiodarone and verapamil in treatment. Br Heart J (1981) 1.46
Dangers of amiodarone and anticoagulant treatment. Br Med J (Clin Res Ed) (1981) 1.35
Effects of amiodarone on sinus node in man. Br Heart J (1979) 1.33
Amiodarone in the treatment of refractory supraventricular and ventricular arrhythmias. Postgrad Med J (1979) 1.31
Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol (2001) 1.30
Antiarrhythmic actions of meptazinol, a partial agonist at opiate receptors, in acute myocardial ischaemia. Br J Pharmacol (1983) 1.21
Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol (2000) 1.13
Differential actions on rabbit nodal, atrial, Purkinje cell and ventricular potentials of melperone, a bradycardic agent delaying repolarization: effects of hypoxia. Br J Pharmacol (1982) 1.13
Alveolitis after treatment with amiodarone. Br Med J (Clin Res Ed) (1982) 1.13
Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opin Emerg Drugs (2009) 1.12
Amiodarone and thyroid hormone metabolism. Postgrad Med J (1986) 1.09
Effects of acute and chronic beta-receptor blockade on ventricular repolarisation in man. Br Heart J (1981) 1.07
Effects on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia. Br J Pharmacol (1982) 1.05
High-performance liquid chromatographic measurement of amiodarone and desethylamiodarone in small tissue samples after enzymatic digestion. J Clin Pathol (1983) 1.00
Best practice in primary care pathology: review 4. J Clin Pathol (2006) 1.00
Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart. Br J Pharmacol (1995) 0.98
Clinical, haemodynamic, and antiarrhythmic effects of long term treatment with amiodarone of patients in heart failure. Br Heart J (1987) 0.97
Clinical antiarrhythmic effects of amiodarone in patients with resistant paroxysmal tachycardias. Br Heart J (1980) 0.97
Acute prolongation of myocardial refractoriness by sotalol. Br Heart J (1982) 0.97
The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis. Cardiovasc Res (2015) 0.95
Evaluation of drug-induced changes in myocardial repolarisation using the paced evoked response. Br Heart J (1982) 0.94
Clinical electrophysiological effects of atenolol--a new cardioselective beta-blocking agent. Br Heart J (1978) 0.94
Resting, and rate-dependent depression of Vmax of guinea-pig ventricular action potentials by amiodarone and desethylamiodarone. Br J Pharmacol (1987) 0.93
Electrophysiological effects of propafenone in untreated and propafenone-pretreated guinea-pig atrial and ventricular muscle fibres. Br J Pharmacol (1985) 0.93
Management of amiodarone-related thyroid problems. Ther Adv Endocrinol Metab (2011) 0.91
QT and action potential duration. Br Heart J (1982) 0.90
The role of thyroid hormone nuclear receptors in the heart: evidence from pharmacological approaches. Heart Fail Rev (2008) 0.88
Comparison of the chronic and acute effects of amiodarone on the calcium and potassium currents in rabbit isolated cardiac myocytes. Br J Pharmacol (1996) 0.87
Use of amiodarone in the postmyocardial infarction patient. Tex Heart Inst J (1995) 0.86
Chemosensitization as a means to augment commercial antifungal agents. Front Microbiol (2012) 0.86
Does amiodarone affect heart rate by inhibiting the intracellular generation of triiodothyronine from thyroxine? Br J Pharmacol (1984) 0.86
Effects on cardiac muscle of the -adrenoceptor blocking drugs INPEA and LB46 in relation to their local anaesthetic action on nerve. Br J Pharmacol (1971) 0.85
Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. Vasc Health Risk Manag (2010) 0.85
Alterations to the electrical activity of atrial muscle isolated from the rat heart, produced by exposure in vitro to amiodarone. Br J Pharmacol (1984) 0.83
Effects of antiarrhythmic drugs on ventricular fibrillation thresholds of normal and ischaemic myocardium in the anaesthetized rat. Br J Pharmacol (1983) 0.83
Amiodarone prophylaxis for tachycardias after coronary artery surgery: a randomised, double blind, placebo controlled trial. Br Heart J (1993) 0.82
The effects on cardiac muscle and nerve of a fluorinated decahydroquinoline derivative, L7810, rapidly absorbed after oral administration. Br J Pharmacol (1973) 0.82
Acute effects of amiodarone upon the canine sinus node and atrioventricular junctional region. J Clin Invest (1983) 0.81
Evaluation of antagonism of aconitine-induced dysrhythmias in mice as a method of detecting and assessing antidysrhythmic activity. Br J Pharmacol (1980) 0.80
Intravenous amiodarone in atrial fibrillation complicating myocardial infarction. Br Med J (Clin Res Ed) (1982) 0.80
Block of cardiac sodium channels by amiodarone studied by using Vmax of action potential in single ventricular myocytes. Br J Pharmacol (1991) 0.80
Amiodarone in long term prophylaxis. Drugs (1991) 0.79
Antagonism of thyroid hormone action by amiodarone in rat pituitary tumor cells. J Clin Invest (1989) 0.79
Effects of class III antiarrhythmic drugs on the Na(+)-activated K+ channels in guinea-pig ventricular cells. Br J Pharmacol (1996) 0.79
Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm. Relation to left atrial size. Br Heart J (1980) 0.79
The effect of prolonged treatment with oxyfedrine on intracellular potentials and on other features of cardiac function in rabbits and guinea-pigs. Br J Pharmacol (1973) 0.78
Effects of long-term oral administration of amiodarone on the electromechanical performance of rabbit ventricular muscle. Br J Pharmacol (1992) 0.78
Effects of metoprolol and amiodarone combination on heart rate, myocardial contractility and coronary flow: Study in isolated perfused rat hearts. Exp Clin Cardiol (2004) 0.77
Tedisamil and lidocaine enhance each other's antiarrhythmic activity against ischaemia-induced arrhythmias in rats. Br J Pharmacol (2003) 0.77
Hypothyroid-like effect of amiodarone in the ventricular myocardium of the rat. Basic Res Cardiol (1987) 0.77
Pleiotropic actions of amiodarone: still puzzling after half a century. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.76
Action of amiodarone over the extension and reversibility of experimental myocardial infarction in pigs. Tex Heart Inst J (1984) 0.75
The effects of amiodarone on the electrocardiogram of the guinea-pig are not explained by interaction with thyroid hormone metabolism alone. Br J Pharmacol (1986) 0.75
Pharmacology of the myocardium: antiarrhythmic therapy. Proc R Soc Med (1976) 0.75
Enhanced Late Na and Ca Currents as Effective Antiarrhythmic Drug Targets. Front Pharmacol (2017) 0.75
Prognostic significance of electrocardiographic findings in angina at rest. Therapeutic implications. Br Heart J (1981) 0.75
Interaction of amiodarone and triiodothyronine on the expression of beta-adrenoceptors in brown adipose tissue of rat. Br J Pharmacol (1999) 0.75
Principal component analysis of HPLC retention data and molecular modeling structural parameters of cardiovascular system drugs in view of their pharmacological activity. Int J Mol Sci (2010) 0.75
Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation. Crit Care (2017) 0.75
Effects of amiodarone and thyroid dysfunction on myocardial calcium, serum calcium and thyroid hormones in the rat. Br J Pharmacol (1987) 0.75
Is there an ideal antiarrhythmic drug? A review--with particular reference to class I antiarrhythmic agents. Postgrad Med J (1985) 0.75
Effects of Amiodarone and N-desethylamiodarone on Cardiac Voltage-Gated Sodium Channels. Front Pharmacol (2016) 0.75
The electrophysiological and contractile responses of hypertrophic cardiomyopathic myocardium. Postgrad Med J (1972) 0.75
Control of recurrent supraventricular tachycardia with amiodarone hydrochloride. Can Med Assoc J (1976) 0.75
Recent trends in the management of life-threatening ventricular arrhythmias. West J Med (1984) 0.75
Amiodarone treatment in patients with ventricular arrhythmias. Drugs (1985) 0.75
When is drug therapy warranted to prevent sudden cardiac death? Drugs (1991) 0.75
Application of quinidine on rat sciatic nerve decreases the amplitude and increases the latency of evoked responses. J Anesth (2013) 0.75
THE EFFECTS ON CARDIAC MUSCLE OF BETA-RECEPTOR ANTAGONISTS IN RELATION TO THEIR ACTIVITY AS LOCAL ANAESTHETICS. Br J Pharmacol Chemother (1965) 3.38
Antifibrillatory action. J Physiol (1962) 3.36
The relevance of beta-receptor blockade to ouabain-induced cardiac arrhythmias. Br J Pharmacol (1969) 3.26
Pharmacology of amiodarone, and anti-anginal drug with a new biological profile. Arzneimittelforschung (1968) 2.54
The effect of altered thyroid state on atrial intracellular potentials. J Physiol (1970) 2.53
LOCAL ANAESTHETIC ACTIVITY OF THE BETA-RECEPTOR ANTAGONIST, PRONETHALOL. Nature (1964) 2.19
[Research on the benzofuran series. XXXVII. Comparative study of transit and metabolism of amiodarone in different species of animals and humans]. Arch Int Pharmacodyn Ther (1969) 2.17
The distribution and metabolism of thyroxine and 3:5:3'-triiodothyronine in the rabbit. J Physiol (1961) 1.94
A comparison of the anti-arrhythmic actions of I.C.I. 50172 and (--)-propranolol and their effects on intracellular cardiac action potentials and other features of cardiac function. Br J Pharmacol (1969) 1.57
A comparison of thyroxine and triiodothyronine as inhibitors of pituitary thyrothrophic hormone secretion in the rabbit. J Physiol (1955) 1.45
The effect of bretylium on intracellular cardiac action potentials in relation to its anti-arrhythmic and local anaesthetic activity. Br J Pharmacol (1969) 1.37
[Research on the benzofuran series. XL. Anti-arrhythmic properties of amiodarone]. Cardiologia (1969) 1.06
The effect of some catecholamine beta-receptor blocking compounds on the toxicity to the heart of ouabain. Br J Pharmacol (1969) 1.06
Some biochemical effects of amiodarone. Arzneimittelforschung (1969) 1.05
[Clinical trial of amiodarone in coronary disorders]. Brux Med (1969) 1.03
[A new anti-angina substance: amiodarone]. Rev Med Liege (1969) 1.01
[A clinical study of amiodarone]. Ann Cardiol Angeiol (Paris) (1970) 0.99
[On a new drug for the management of angina pectoris, Amiodarion]. Wien Med Wochenschr (1968) 0.99
Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med (1995) 3.56
The relevance of beta-receptor blockade to ouabain-induced cardiac arrhythmias. Br J Pharmacol (1969) 3.26
A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol (1970) 2.78
Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med (1994) 2.68
A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol (1984) 2.63
Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol (1995) 2.31
New perspectives in the pharmacologic therapy of cardiac arrhythmias. Prog Cardiovasc Dis (1980) 1.95
Dual effect of disopyramide on atrial and atrioventricular conduction and refractory periods. Br Heart J (1977) 1.94
Classification of antidysrhythmic drugs. Pharmacol Ther B (1975) 1.73
Abscisic Acid localization and metabolism in barley aleurone layers. Plant Physiol (1979) 1.71
Reduction of enzyme levels by propranolol after acute myocardial infarction. Circulation (1978) 1.68
Plasma propranolol concentration in patients with angina and acute myocardial infarction. Clin Exp Pharmacol Physiol (1976) 1.68
Effects of intravenous verapamil on hemodynamics in patients with heart disease. Am Heart J (1977) 1.63
Effects of amiodarone on thyroid function in patients with ischaemic heart disease. Br Heart J (1975) 1.63
Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation (2000) 1.63
Cytologic findings in aspirated hydatid fluid. Acta Cytol (1989) 1.58
Amiodarone and thyroid function. Prog Cardiovasc Dis (1989) 1.55
Review of wheat improvement for waterlogging tolerance in Australia and India: the importance of anaerobiosis and element toxicities associated with different soils. Ann Bot (2008) 1.53
Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J (1974) 1.52
Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol (1999) 1.49
Verapamil: a review of its pharmacological properties and therapeutic use. Drugs (1978) 1.47
Non-Q-wave myocardial infarction-current status. J Assoc Physicians India (1988) 1.40
The effect of bretylium on intracellular cardiac action potentials in relation to its anti-arrhythmic and local anaesthetic activity. Br J Pharmacol (1969) 1.37
The effect of oxprenolol on cardiac intracellular potentials in relation to its anti-arrhythmic, local anaesthetic and other properties. Postgrad Med J (1970) 1.37
A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function. Cardiovasc Res (1972) 1.36
Effects of verapamil on infarct size following experimental coronary occlusion. Cardiovasc Res (1975) 1.32
Effect of altering potassium concentration on the action of lidocaine and diphenylhydantoin on rabbit atrial and ventricular muscle. Circ Res (1971) 1.29
Therapeutic implications of slow-channel blockade in cardiocirculatory disorders. Circulation (1980) 1.26
Control of refractory life-threatening ventricular tachyarrhythmias by amiodarone. Am Heart J (1981) 1.25
Cytopathogenic effect of Trichomonas vaginalis on human vaginal epithelial cells cultured in vitro. Infect Immun (2000) 1.25
Noninvasive identification of a high risk subset of patients with acute inferior myocardial infarction. Am J Cardiol (1980) 1.24
Ionic mechanisms in heart muscle in relation to the genesis and the pharmacological control of cardiac arrhythmias. Pharmacol Rev (1978) 1.23
Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone administration. J Clin Endocrinol Metab (1981) 1.22
Effects of cardioselective beta adrenoceptor blockade on specific airways resistance in normal subjects and in patients with bronchial asthma. Clin Pharmacol Ther (1976) 1.22
Control of cardiac arrhythmias by selective lengthening of repolarization: theoretic considerations and clinical observations. Am Heart J (1985) 1.22
Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol (1999) 1.21
Failure of ST segment elevation to predict severity of acute myocardial infarction. Br Heart J (1976) 1.21
Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart : comparison with amiodarone. Circulation (1999) 1.20
Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics. J Am Coll Cardiol (1986) 1.20
The frequency and prognostic significance of electrocardiographic abnormalities in clinically normal individuals. Prog Cardiovasc Dis (1981) 1.19
Studies on pathogenic and non-pathogenic small free-living amoebae and the bearing of nuclear division on the classification of the order amoebida. Philos Trans R Soc Lond B Biol Sci (1970) 1.19
The effect of delay in propranolol administration on reduction of myocardial infarct size after experimental coronary artery occlusion in dogs. Circulation (1979) 1.17
Cardiospecificity of -receptor blockade. A comparison of the relative potencies on cardiac and peripheral vascular -adrenoceptors of propranolol, of practolol and its ortho-substituted isomer, and of oxprenolol and its para-substituted isomer. Cardiovasc Res (1973) 1.17
Mechanism of rest and nocturnal angina: observations during continuous hemodynamic and electrocardiographic monitoring. Circulation (1979) 1.16
The multiple modes of action of propafenone. Eur Heart J (1984) 1.16
Early effects of gibberellic acid on barley aleurone layers. Biochem Biophys Res Commun (1968) 1.15
Prognostic significance of silent myocardial ischemia in patients with unstable angina. J Am Coll Cardiol (1987) 1.14
Differential actions on rabbit nodal, atrial, Purkinje cell and ventricular potentials of melperone, a bradycardic agent delaying repolarization: effects of hypoxia. Br J Pharmacol (1982) 1.13
Amiodarone: historical development and pharmacologic profile. Am Heart J (1983) 1.12
Diuretic-induced potassium and magnesium deficiency: relation to drug-induced QT prolongation, cardiac arrhythmias and sudden death. J Hypertens (1992) 1.12
Electrophysiologic effects of amiodarone: experimental and clinical observation relative to serum and tissue drug concentrations. Am Heart J (1984) 1.11
Local anaesthetic and anti-arrhythmic actions of alprenolol relative to its effect on intracellular potentials and other properties of isolated cardiac muscle. Br J Pharmacol (1970) 1.10
Electrophysiological effects of alpha-adrenoceptor antagonists in rabbit sino-atrial node, cardiac Purkinje cells and papillary muscles. Br J Pharmacol (1984) 1.10
Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med (2000) 1.09
Voltage- and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide. Cardiovasc Res (1983) 1.08
The effect of some catecholamine beta-receptor blocking compounds on the toxicity to the heart of ouabain. Br J Pharmacol (1969) 1.06
Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. Circulation (1982) 1.05
Effects on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia. Br J Pharmacol (1982) 1.05
Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias. Drugs (1979) 1.05
Left ventricular ejection fraction determined by radionuclide ventriculography in early stages of first transmural myocardial infarction. Relation to short-term prognosis. Am J Cardiol (1980) 1.05
Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol (1995) 1.04
Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease. Am J Cardiol (1981) 1.04
Beta-adrenergic receptor blocking drugs in cardiac arrhythmias. Drugs (1974) 1.02
Amiodarone in refractory life-threatening ventricular arrhythmias. Ann Intern Med (1983) 1.02
QTLs associated with root traits increase yield in upland rice when transferred through marker-assisted selection. Theor Appl Genet (2012) 1.01
Pharmacological basis for the therapeutic applications of slow-channel blocking drugs. Angiology (1982) 1.00
Effects of selective alpha 1-, alpha 2-, beta 1-and beta 2-adrenoceptor stimulation on potentials and contractions in the rabbit heart. J Physiol (1984) 0.99
Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. Circulation (1985) 0.98
Calcium antagonists. Clinical use in the treatment of arrhythmias. Drugs (1983) 0.97
When is QT prolongation antiarrhythmic and when is it proarrhythmic? Am J Cardiol (1989) 0.97
The effects of palmitate on intracellular potentials recorded from Langendorff-erfused guinea-pig hearts in normoxia and hypoxia, and during perfusion at reduced rate of flow. J Mol Cell Cardiol (1977) 0.97
The mechanism of action of calcium antagonists relative to their clinical applications. Br J Clin Pharmacol (1986) 0.96
Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease. Am Heart J (1985) 0.96
Kinetoplastid membrane protein-11 (KMP-11) is differentially expressed during the life cycle of African trypanosomes and is found in a wide variety of kinetoplastid parasites. Mol Biochem Parasitol (1995) 0.95
Pharmacological mapping of regional effects in the rabbit heart of some new antiarrhythmic drugs. Br J Pharmacol (1983) 0.94
Changes in myocardial blood flow and S-T segment elevation following coronary artery occlusion in dogs. Circ Res (1975) 0.94
Effects of amiodarone and L8040, novel antianginal and antiarrhythmic drugs, on cardiac and coronary haemodynamics and on cardiac intracellular potentials. Clin Exp Pharmacol Physiol (1976) 0.94
Subgroups of class 1 antiarrhythmic drugs. Eur Heart J (1984) 0.93
Synthesis of a ubiquitously present new HSP60 family protein is enhanced by heat shock only in the Malpighian tubules of Drosophila. Experientia (1996) 0.92
Delayed ventricular repolarization as an anti-arrhythmic principle. Eur Heart J (1985) 0.92
Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. J Am Coll Cardiol (1984) 0.92
Effects of amiodarone and its metabolite, desethylamiodarone, on the electrophysiologic properties of isolated cardiac muscle. J Cardiovasc Pharmacol (1986) 0.92
Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol (1994) 0.91
Second-generation calcium antagonists: search for greater selectivity and versatility. Am J Cardiol (1985) 0.91
Phospholipid metabolism of cultured Trichomonas vaginalis and Tritrichomonas foetus. Mol Biochem Parasitol (1991) 0.91
Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram. Am Heart J (1975) 0.91
Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions. Am J Cardiol (1999) 0.90
Free fatty acids of human meconium. Biol Neonate (1986) 0.90
Editors' roundtable: Current formulas for P & T Committee success (Part 1). Hosp Formul (1987) 0.90
Special article. The role of beta-adrenergic blockade in myocardial infarction. Prog Cardiovasc Dis (1974) 0.90
Synthesis and biological activity of isodithiobiurets, dithiobiurets, and dithiazoles. Pharm Res (1987) 0.90
Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. Circulation (1996) 0.90
QT and action potential duration. Br Heart J (1982) 0.90
A comparison of the actions of ICI66082 and propranolol on cardiac and peripheral beta-adrenoceptors. Eur J Pharmacol (1975) 0.90
Amiodarone and post-MI patients. Circulation (1993) 0.89
Biosynthesis of the novel fatty acid, 17-methyl-cis-9,10-methyleneoctadecanoic acid, by the parasitic protozoan, Herpetomonas megaseliae. Lipids (1983) 0.89